Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
99 questions in 10 reviews · Fertility Regulation
current versionsNo studies 99 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid) Ibuprofen vs placebo Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid) Aspirin vs paracetamol Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid) Adverse events or side effects Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid) Menstrual blood loss % occurrence of heavy menstrual bleeding (alkaline hematin method) Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid) Menstrual blood loss % occurrence heavy menstrual bleeding (PBAC score) Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events or side effects Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Menstrual blood loss Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mifepristone vs vitamin B Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Naproxen vs estradiol Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids) Adverse events or side effects Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Interventions (ibuprofen, tolfenamic acid) vs placebo Ibuprofen vs placebo Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pregabalin 300 mg vs placebo Complete abortion rate ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pregabalin 300 mg vs placebo Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pregabalin 300 mg vs placebo Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Gastrointestinal side effects (nausea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 800 mg vs placebo Gastrointestinal side effects (diarrhoea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 800 mg vs placebo Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 800 mg vs placebo Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 800 mg vs placebo Patient satisfaction with analgesia ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 800 mg vs placebo Patient satisfaction with abortion care overall ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Gastrointestinal side effects (nausea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Gastroinestinal side effects (vomiting) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Gastrointestinal side effects (vomiting) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Gastrointestinal side effects (diarrhoea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Patient satisfaction with analgesia ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ambulation vs non‐ambulation Patient satisfaction with abortion care overall ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Therapeutic ibuprofen 800 mg vs prophylactic ibuprofen 800 mg women having medical abortion before 14 weeks? gestation Gastrointestinal side effects (diarrhoea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Gastrointestinal side effects (diarrhoea) ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Therapeutic ibuprofen 800 mg vs prophylactic ibuprofen 800 mg women having medical abortion before 14 weeks? gestation Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Therapeutic ibuprofen 800 mg vs prophylactic ibuprofen 800 mg women having medical abortion before 14 weeks? gestation Patient satisfaction with analgesia ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Patient satisfaction with analgesia ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol 2000 mg Patient satisfaction with abortion care overall ‐ not reported · women having medical abortion before 14 weeks' gestation Pain management for medical abortion before 14 weeks’ gestation (2022) · Cochrane | no estimate extracted | NR | No studies |
Critical outcomes for medical abortion offered in pharmacy vs clinic‐based settings Outcomesa Medical abortion offered in pharmacy versus clinic‐based settings (2021) · Cochrane | no estimate extracted | NR | No studies |
Critical outcomes for medical abortion offered in pharmacy vs clinic‐based settings Additional surgical interventions required Medical abortion offered in pharmacy versus clinic‐based settings (2021) · Cochrane | no estimate extracted | NR | No studies |
Self‐administered medical abortion vs provider‐administered medical abortion Any complication requiring surgical intervention ‐ RCT · women of reproductive age (15 to 49 years) seeking induced abortion Self‐administered versus provider‐administered medical abortion (2020) · Cochrane | no estimate extracted | NR | No studies |
Mid‐dose mifepristone (25 mg‐50 mg) vs levonorgestrel 1.5 mg Specific side effect ‐ vomiting · women seeking emergency contraception Interventions for emergency contraception (2019) · Cochrane | no estimate extracted | NR | No studies |
Mifepristone (all doses) vs Yuzpe Specific side effects ‐ spotting/bleeding after treatment · women seeking emergency contraception Interventions for emergency contraception (2019) · Cochrane | no estimate extracted | NR | No studies |
Ulipristal acetate (all doses) vs levonorgestrel Any side effect · women seeking emergency contraception Interventions for emergency contraception (2019) · Cochrane | no estimate extracted | NR | No studies |
Single‐dose levonorgestrel vs split‐dose levonorgestrel Any side effect · women seeking emergency contraception Interventions for emergency contraception (2019) · Cochrane | no estimate extracted | NR | No studies |
Copper intrauterine device vs mifepristone (all doses) Specific side effects ‐ nausea · women seeking emergency contraception Interventions for emergency contraception (2019) · Cochrane | no estimate extracted | NR | No studies |
Copper intrauterine device vs mifepristone (all doses) Specific side effects ‐ vomiting · women seeking emergency contraception Interventions for emergency contraception (2019) · Cochrane | no estimate extracted | NR | No studies |
Copper intrauterine device vs mifepristone (all doses) Specific side effects ‐ spotting/bleeding after treatment · women seeking emergency contraception Interventions for emergency contraception (2019) · Cochrane | no estimate extracted | NR | No studies |
Reminders (+/‐ educational information) vs usual family planning care Pregnancy · Women of reproductive age seeking to avoid pregnancy Strategies to improve adherence and continuation of shorter‐term hormonal methods of contraception (2019) · Cochrane | no estimate extracted | NR | No studies |
Intensive counseling vs usual family planning care Adherence to method use · Women of reproductive age seeking to avoid pregnancy Strategies to improve adherence and continuation of shorter‐term hormonal methods of contraception (2019) · Cochrane | no estimate extracted | NR | No studies |
Reminders (+/‐ educational information) vs usual family planning care Rates of discontinuation due to adverse events · Women of reproductive age seeking to avoid pregnancy Strategies to improve adherence and continuation of shorter‐term hormonal methods of contraception (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR OC: oral contraceptive · perimenopausal women with need for contraception Progestin‐only contraceptives: effects on weight (2016) · Cochrane | no estimate extracted | NR | No studies |